KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $735.1 million.

  • Regeneron Pharmaceuticals' Change in Accured Expenses rose 290.53% to $759.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $987.1 million, marking a year-over-year increase of 166.21%. This contributed to the annual value of $735.1 million for FY2024, which is 22.80% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Change in Accured Expenses of $735.1 million as of FY2024, which was up 22.80% from $598.6 million recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Change in Accured Expenses high stood at $866.1 million for FY2021, and its period low was -$138.4 million during FY2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was $598.6 million (2023), whereas its average is $398.4 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Change in Accured Expenses surged by 628.43% in 2021, and later tumbled by 115.98% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $118.9 million in 2020, then soared by 628.43% to $866.1 million in 2021, then crashed by 115.98% to -$138.4 million in 2022, then skyrocketed by 532.51% to $598.6 million in 2023, then increased by 22.80% to $735.1 million in 2024.